{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T10:21:21Z","timestamp":1793614881404,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-020-0301-x","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T14:12:25Z","timestamp":1583503945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Bright PD-1 expression by flow cytometry is a powerful tool for diagnosis and monitoring of angioimmunoblastic T-cell lymphoma"],"prefix":"10.1038","volume":"10","author":[{"given":"Mariko","family":"Yabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neval","family":"Ozkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Huet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine D.","family":"Pichardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison J.","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-5256","authenticated-orcid":false,"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Roshal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,6]]},"reference":[{"key":"301_CR1","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose, J., Armitage, J. & Weisenburger, D. International T-Cell Lymphoma Project: International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J. Clin. Oncol. 26, 4124\u20134130 (2008).","journal-title":"J. Clin. Oncol."},{"key":"301_CR2","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","volume":"109","author":"L de Leval","year":"2007","unstructured":"de Leval, L. et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109, 4952\u20134963 (2007).","journal-title":"Blood"},{"key":"301_CR3","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1182\/blood-2005-03-1083","volume":"106","author":"KL Grogg","year":"2005","unstructured":"Grogg, K. L. et al. Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells? Blood 106, 1501\u20131502 (2005).","journal-title":"Blood"},{"key":"301_CR4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/j.1365-2141.2009.08003.x","volume":"148","author":"L de Leval","year":"2010","unstructured":"de Leval, L., Gisselbrecht, C. & Gaulard, P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br. J. Haematol. 148, 673\u2013689 (2010).","journal-title":"Br. J. Haematol."},{"key":"301_CR5","unstructured":"Dogan A., et.al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edn) 407\u2013412 (IARC, Lyon, 2017)."},{"key":"301_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/PAS.0b013e31820065c9","volume":"35","author":"DM Dorfman","year":"2011","unstructured":"Dorfman, D. M. & Shahsafaei, A. CD200 (OX-2 membrane glycoprotein) is expressed by follicular T helper cells and in angioimmunoblastic T-cell lymphoma. Am. J. Surg. Pathol. 35, 76\u201383 (2011).","journal-title":"Am. J. Surg. Pathol."},{"key":"301_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/ajcp\/aqv017","volume":"145","author":"JA David","year":"2016","unstructured":"David, J. A. & Huang, J. Z. Diagnostic utility of flow cytometry analysis of reactive T cells in nodular lymphocyte-predominant hodgkin lymphoma. Am. J. Clin. Pathol. 145, 107\u2013115 (2016).","journal-title":"Am. J. Clin. Pathol."},{"key":"301_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/cyto.b.21529","volume":"94","author":"S de Mel","year":"2018","unstructured":"de Mel, S. et al. The utility of flow cytometry in differentiating NK\/T cell lymphoma from indolent and reactive NK cell proliferations. Cytometry B Clin. Cytom. 94, 159\u2013168 (2018).","journal-title":"Cytometry B Clin. Cytom."},{"key":"301_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/1097-0320(20000615)42:3<180::AID-CYTO4>3.0.CO;2-0","volume":"42","author":"S Serke","year":"2000","unstructured":"Serke, S. et al. Circulating CD4+ T lymphocytes with intracellular but no surface CD3 antigen in five of seven patients consecutively diagnosed with angioimmunoblastic T-cell lymphoma. Cytometry 42, 180\u2013187 (2000).","journal-title":"Cytometry"},{"key":"301_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/hon.2080","volume":"32","author":"A Singh","year":"2014","unstructured":"Singh, A. et al. Peripheral blood sCD3(-) CD4(+) T cells: a useful diagnostic tool in angioimmunoblastic T cell lymphoma. Hematol. Oncol. 32, 16\u201321 (2014).","journal-title":"Hematol. Oncol."},{"key":"301_CR11","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1309\/MC7QRGPTV0LRR98X","volume":"128","author":"A Stacchini","year":"2007","unstructured":"Stacchini, A. et al. The usefulness of flow cytometric CD10 detection in the differential diagnosis of peripheral T-cell lymphomas. Am. J. Clin. Pathol. 128, 854\u2013864 (2007).","journal-title":"Am. J. Clin. Pathol."},{"key":"301_CR12","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/modpathol.2016.113","volume":"29","author":"M Alikhan","year":"2016","unstructured":"Alikhan, M. et al. Peripheral T-cell lymphomas of follicular helper T-cell type frequently display an aberrant CD3(-\/dim)CD4(+) population by flow cytometry: an important clue to the diagnosis of a Hodgkin lymphoma mimic. Mod. Pathol. 29, 1173\u20131182 (2016).","journal-title":"Mod. Pathol."},{"key":"301_CR13","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.3109\/10428194.2016.1170827","volume":"57","author":"S Loghavi","year":"2016","unstructured":"Loghavi, S. et al. Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology. Leuk. Lymphoma 57, 2804\u20132812 (2016).","journal-title":"Leuk. Lymphoma"},{"key":"301_CR14","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/leu.2012.120","volume":"26","author":"JJ van Dongen","year":"2012","unstructured":"van Dongen, J. J. et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26, 1908\u20131975 (2012).","journal-title":"Leukemia"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0301-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0301-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0301-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:26:16Z","timestamp":1670250376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0301-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,6]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["301"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-0301-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,6]]},"assertion":[{"value":"13 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.J.M.: Consultancy from ADC Therapeutics, Erytech Pharma, Bristol-Myers Squibb, Cell Medica, Takeda Pharmaceuticals, Kyowa Hakko Kirin Pharma, miRagen Therapeutics Inc, Seattle Genetics. Research Funding from Bristol-Myers Squibb, Incyte, Kyowa Hakko Kirin Pharma, miRagen Therapeutics Inc, Seattle Genetics and Merck. Honoraria from Seattle Genetics. S.M.H.: Clinical research support\/ Data safety monitoring board from ADC Therapeutics, AILERON, BeiGene, Celgene Corporation, Daiichi- Sankyo Co., Forty Seven, Inc., GlaxoSmithKline, Merck & Co., Inc., Miragen, Portola Pharmaceuticals, Inc., Seattle Genetics, Inc., Takeda\/ Millennium, Trillium and Verastem. Scientific advisory boards, consultant or expert witness from Astex Pharmaceuticals, Celgene Corporation, Kura Oncology, Inc., Kyowa Hakko Kirin Co., Ltd., Portola Pharmaceuticals, Inc., Seattle Genetics, Inc., Takeda Pharmaceuticals North America, Inc. and Verastem. A.D.: Personal fees from Roche, Corvus Pharmaceuticals, Physicians\u2019 Education Resource, Seattle Genetics, Peerview Institute, Oncology Specialty Group, Pharmacyclics, Celgene, Novartis, Takeda, EUSA Pharma and research grants from National Cancer Institute and Roche. M.R.: Physicians\u2019 Education Resource: Other: Provision of services; Celgene: Other: Provision of Services; Auron Therapeutics: Equity Ownership, Other: Provision of services. Other authors declare no relevant financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"32"}}